MOG antibody-associated diseases
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published January 22, 2015.
Author Disclosures
- Markus Reindl, PhD and
- Kevin Rostasy, MD
- Markus Reindl, PhD and
NONE
NONE
NONE
PLOS ONE, academic editor, 2012-Current Medicinal Chemistry, editorial board, 2006-2012 Autoimmune Diseases, 2012-2013
NONE
NONE
NONE
NONE
NONE
Dr. Reindl and Medical University of Innsbruck receive payments for antibody assays (AQP4 and antineuronal antibodies) and for AQP4 antibody validation experiments organized by Euroimmun.
NONE
NONE
Austrian Science Fund (FWF), grants W1206 and I916 Austrian Federal Ministry of Science grant ?BIG-WIG MS? Jubilaeumsfonds of the Austrian National Bank, grants 14158 and 15198
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kevin Rostasy, MD
Scientific adviser on Fingolimod project-Novartis
NONE
Merck-Serono- Symposium speaker GNP annual meeting 2013, Innsbruck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria; and Division of Pediatric Neurology (K.R.), Children's Hospital Datteln, University Witten/Herdecke, Datteln, Germany.
- Correspondence to Dr. Reindl: markus.reindl{at}i-med.ac.at
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014 -
Article
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritisSudarshini Ramanathan, Stephen W. Reddel, Andrew Henderson et al.Neurology - Neuroimmunology Neuroinflammation, October 29, 2014 -
Article
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeletonRussell C. Dale, Esther M. Tantsis, Vera Merheb et al.Neurology - Neuroimmunology Neuroinflammation, May 22, 2014 -
Views & Reviews
International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al.Neurology, June 19, 2015